Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0E7FM
|
|||
| Former ID |
DNCL002734
|
|||
| Drug Name |
GTx-758
|
|||
| Indication | Prostate cancer [ICD-11: 2C82.0; ICD-9: 185] | Phase 2 | [1] | |
| Company |
GTx
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C19H13F2NO3
|
|||
| Canonical SMILES |
C1=CC(=CC=C1N(C2=CC=C(C=C2)F)C(=O)C3=CC(=C(C=C3)O)F)O
|
|||
| InChI |
1S/C19H13F2NO3/c20-13-2-4-14(5-3-13)22(15-6-8-16(23)9-7-15)19(25)12-1-10-18(24)17(21)11-12/h1-11,23-24H
|
|||
| InChIKey |
FBCQEUMZZNVQKD-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 938067-78-8
|
|||
| PubChem Compound ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01326312) Effect of GTx-758 on Total and Free Testosterone Levels in Men With Prostate Cancer. U.S. National Institutes of Health. | |||
| REF 2 | Selective estrogen receptor alpha agonist GTx-758 decreases testosterone with reduced side effects of androgen deprivation therapy in men with advanced prostate cancer. Eur Urol. 2015 Feb;67(2):334-41. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.